Autoantibodies
Researchers at the Walter and Eliza Hall Institute of Medical Research have discovered that autoantibodies, specifically targeting type I interferons, are a key feature in severe COVID-19 cases and hospitalizations. The study found that hospitalized patients had significantly higher levels of autoantibodies targeting various proteins, including ACE2, MPO, IFNO, IFNa1,
Diseases
Researchers at the Walter and Eliza Hall Institute of Medical Research have discovered that autoantibodies, specifically targeting type I interferons, are a key feature in severe COVID-19 cases and hospitalizations. The study found that hospitalized patients had significantly higher levels of autoantibodies targeting various proteins, including ACE2, MPO, IFNO, IFNa1,
Diseases
Monte Rosa Therapeutics, a clinical-stage biotechnology company, recently announced the presentation of preclinical data on MRT-6160, a rationally designed molecular glue degrader (MGD), at the ACR Convergence 2025 conference. The data demonstrate the potential of MRT-6160 to address multiple autoimmune and inflammatory diseases, including systemic lupus erythematosus, Sjogren's
Diseases
Research published in the Proceedings of the National Academy of Sciences (PNAS) reveals that immunoglobin G (IgG) cleaving enzymes can target the primary pathogenic mechanism in myasthenia gravis by degrading immunoglobulins in circulation and immune complexes. Seismic Therapeutic's engineered pan-IgG enzymes successfully cleaved pathogenic AChR autoantibodies, thereby inhibiting
Diseases
AbelZeta Pharma, a global clinical-stage biopharmaceutical company, announced that clinical data from the first-in-human Phase I trial of C-CAR168 in patients with refractory autoimmune diseases will be presented at the American College of Rheumatology (ACR) Convergence 2025. The presentation, titled "Anti-CD20/BCMA Bispecific CAR-T Cell Therapy Promotes Immune Reset
Diseases
A new report from Tongji University highlights the potential of glucagon-like peptide-1 (GLP-1) receptor agonists in treating autoimmune and autoinflammatory diseases. GLP-1 receptor agonists, or GLP-1RAs, have already shown effectiveness in managing type 2 diabetes mellitus and obesity. However, research suggests that these drugs may also have beneficial effects on
Dementia
Researchers from Capital Medical University in Beijing, People's Republic of China, have published a new study on neurodegenerative dementia, shedding light on the complex interactions between autoantibodies and cognitive function. The study, published in Neurology and Therapy, explored the clinical characteristics of patients with autoantibody-positive neurodegenerative dementia and
Autoimmunity
AbelZeta Pharma, a global clinical-stage biopharmaceutical company, announced that clinical data from the first-in-human Phase I trial of C-CAR168 in patients with refractory autoimmune diseases will be presented at the American College of Rheumatology (ACR) Convergence 2025. The presentation will highlight the potential of C-CAR168 to simultaneously target autoantibody-producing plasma
Diseases
Researchers at Sutter Roseville Medical Center in Roseville, California, have reported a case of a 44-year-old African American female who developed anti-glomerular basement membrane (anti-GBM) disease after contracting COVID-19. The patient presented with acute kidney injury, hematuria, and shortness of breath, and despite aggressive therapy, renal recovery was not achieved.
Diseases
Research from AstraZeneca has shed light on the pathogenic roles of Th17 cells in autoimmune diseases such as multiple sclerosis, inflammatory bowel disease, and psoriasis. Studies have shown that targeting Th17 cell-related cytokines, such as IL-17 and IL-23, can provide clinical benefits in treating inflammatory diseases. The research highlights the
Diseases
Research at the National Institute of Neuroscience in Tokyo, Japan, has shed new light on the role of thyroid hormone receptor beta (TR-b) signaling in autoimmune disease. Investigators found that TR-b signaling controls the function of pathogenic T helper (Th) cells, which are involved in the development of autoimmune diseases
Diseases
Research has documented a case of statin-associated necrotizing autoimmune myopathy (NAM) unmasked by statin re-exposure in a 65-year-old man. The patient had experienced worsening, painless proximal muscle weakness and significant creatine kinase (CK) elevation shortly after resuming statin therapy following a temporary discontinuation. Diagnostic workup revealed positive 3-hydroxy-3-methylglutaryl-CoA reductase antibodies
